List of Excipients in Branded Drug ZITHROMAX

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Pfizer Laboratories Div Pfizer Inc	ZITHROMAX	azithromycin dihydrate	0069-0400	ANHYDROUS CITRIC ACID
Pfizer Laboratories Div Pfizer Inc	ZITHROMAX	azithromycin dihydrate	0069-0400	SODIUM HYDROXIDE
Pfizer Laboratories Div Pfizer Inc	ZITHROMAX	azithromycin dihydrate	0069-3060	ALUMINUM OXIDE

Generic Drugs Containing ZITHROMAX

Company	Ingredient	NDC	Excipient
DIRECT RX	azithromycin	61919-555	CELLULOSE, MICROCRYSTALLINE
DIRECT RX	azithromycin	61919-555	CROSCARMELLOSE SODIUM
DIRECT RX	azithromycin	61919-555	HYDROXYPROPYL CELLULOSE

What are the Most Frequently-Used Excipients in ZITHROMAX?

# Of NDCs	Excipient
2	CELLULOSE, MICROCRYSTALLINE
2	CROSCARMELLOSE SODIUM
2	HYDROXYPROPYL CELLULOSE

Excipient Strategy and Commercial Opportunities for ZITHROMAX

Last updated: February 25, 2026

What is the excipient profile used in ZITHROMAX?

ZITHROMAX (azithromycin) oral formulation employs specific excipients to ensure stability, bioavailability, and shelf-life. Its formulation includes:

• Microcrystalline cellulose: Disintegrant and binder that enhances tablet integrity.
• Croscarmellose sodium: Superdisintegrant facilitating rapid dissolution.
• Lactose monohydrate: filler providing bulk.
• Magnesium stearate: lubricant reducing friction during manufacturing.
• Hydroxypropyl cellulose: binder and film-former.
• Colorants and coatings: for identification and stability.

The liquid formulation also contains excipients such as:

• Propylene glycol: solvent and humectant.
• Polysorbate 80: emulsifier.
• Flavoring agents and sweeteners: to mask bitterness.

How does excipient choice influence ZITHROMAX's performance?

Excipients impact drug stability, absorption, and patient compliance:

• Stability: Lactose and certain coatings protect azithromycin from moisture and degradation.
• Bioavailability: Superdisintegrants like croscarmellose sodium facilitate rapid drug release.
• Manufacturability: Lubricants such as magnesium stearate ease tablet compression.
• Patient Experience: Flavoring and sweeteners improve palatability, especially in pediatric formulations.

Are there opportunities to optimize excipient strategies?

Yes. Opportunities include:

1. Replacing lactose with alternative fillers

Lactose intolerance limits use in some patient populations. Alternatives like microcrystalline cellulose, mannitol, or erythritol could broaden market access.

2. Integrating novel disintegrants

Superdisintegrants such as sodium starch glycolate or modified alginates may reduce disintegration times, improving onset of action.

3. Enhancing moisture resistance

Incorporating moisture barriers like ethylcellulose coatings or desiccants enhances stability, especially for liquid formulations.

4. Developing flexible formulations

Using advanced excipients to produce sustained-release or chewable formulations could expand market segments.

What are the commercial implications of excipient choices?

• Regulatory approval: Altering excipients like lactose can require additional filings. Selecting Generally Recognized As Safe (GRAS) excipients streamlines approval.
• Patent opportunities: Novel excipient combinations may enable new patents, extending the product lifecycle.
• Market expansion: Excipient modifications can cater to specific populations, such as diabetics or lactose-intolerant individuals.
• Cost control: Excipients influence manufacturing cost and scalability. Choosing cost-effective yet high-performance excipients enhances margins.

How does ZITHROMAX compare to competitors in excipient strategy?

Competitors such as clarithromycin or erythromycin-based formulations also incorporate disintegrants, fillers, and binders similar to ZITHROMAX. Innovation focus areas for competitors include:

• Sugar-free formulations targeting diabetics.
• Sustained-release versions for longer dosing intervals.
• Liquid formulations with improved stability and flavor.

ZITHROMAX's positioning depends on optimizing excipient choices to improve stability, bioavailability, and patient adherence.

Key Takeaways

• Excipients in ZITHROMAX play critical roles in stability, bioavailability, and patient acceptance.
• Opportunities exist in substituting lactose, enhancing disintegration, and improving moisture resistance.
• Excipient modifications can create patent avenues, expand markets, and improve cost efficiency.
• Careful regulatory navigation and market targeting are essential when altering excipient strategies.

FAQs

1. Can ZITHROMAX formulations be optimized to reduce manufacturing costs?

Yes. Selecting cost-effective excipients that meet quality standards can lower production expenses without compromising performance.

2. What excipient restrictions exist for pediatric formulations?

Pediatric formulations avoid certain excipients like lactose or preservatives linked to adverse effects. Alternative fillers and sweeteners are employed.

3. Are bioequivalence concerns significant when changing excipients?

Yes. Regulatory agencies require demonstrating bioequivalence, especially for modifications affecting dissolution or absorption.

4. How does excipient choice affect shelf life?

Excipients help prevent moisture ingress, oxidative degradation, and microbial growth, thus prolonging shelf life.

5. Is there demand for sustained-release or alternative dosage forms for azithromycin?

Yes. Extended-release formulations can reduce dosing frequency and improve adherence, representing a growth avenue.

References

[1] U.S. Food and Drug Administration. (2021). Guidance for industry: Excipients in approved drug and biological products.
[2] World Health Organization. (2019). WHO model formulary.
[3] Market Research Future. (2022). Pharmaceutical excipients market analysis.